

## What does BARDA do for global health R&D?

The Biomedical Advanced Research and Development Authority (BARDA) supports the development of vaccines, drugs, and other medical countermeasures (MCMs) to protect Americans against threats to public health, including emerging infectious diseases, pandemic influenza, and antimicrobial resistance (AMR).

## Why is BARDA's role in global health R&D important?


BARDA works with industry and other partners to bridge the "valley of death" between basic research and product development, where research and development (R&D) efforts most often fail. Through unique contracting and incentive mechanisms, BARDA's partnerships ensure promising research is translated into urgently needed medical products by creating commercial incentives for developers that would otherwise not exist. During the COVID-19 pandemic, BARDA's prominence and funding has grown exponentially as the agency was charged with leading the US government's MCM R&D portfolio, demonstrating how—with sufficient, sustained funding—BARDA is uniquely equipped to advance products against a range of other global health threats.

## BARDA support has helped advance:

**40<sup>+</sup>** FDA-approved or authorized products for Ebola, Zika, & COVID-19

**92** projects to accelerate innovations for AMR

## R&D investment by health area



2017-2021 data. Does not reflect investments in antimicrobial resistance or influenza.

## IMPACT OF INVESTMENT



### COVID-19

Led US **COVID-19 product development** efforts for vaccines, diagnostics, and therapeutics, supporting dozens of innovations, including **all vaccines** approved or authorized by the US Food and Drug Administration (FDA).



### EBOLA

Development of the world's first **Ebola vaccine**, as well as **two Ebola treatments** and **one rapid diagnostic test** approved by the FDA.



### AMR

Accelerating **antibacterial research** through the CARB-X public-private partnership, which has supported **92 projects in 12 countries**, to build the **world's largest early development pipeline of antibacterial innovations**.



### MPOX

Development of the only FDA-approved **vaccine for smallpox/Mpox**, which was deployed during the 2022–2023 outbreak.



### ZIKA

Development of **six FDA-approved diagnostics**, including tests to **identify infection** and **screen blood supplies**.



### INFLUENZA

**Strengthening manufacturing capacity** in low- and middle-income countries to enable rapid production of seasonal and **pandemic influenza vaccines**.